Sarah E Monsell1, Charles Mock2, Jason Hassenstab2, Catherine M Roe2, Nigel J Cairns2, John C Morris2, Walter Kukull2. 1. From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO. smonsell@u.washington.edu. 2. From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.
Abstract
OBJECTIVE: To determine whether asymptomatic persons with Alzheimer disease (AD) neuropathologic change differ in the trajectory of their cognitive performance compared to asymptomatic persons without AD neuropathologic change. METHODS: Longitudinal performance on standard neuropsychological tests was examined in participants who died within 2 years of their last cognitive assessment and who were never diagnosed with mild cognitive impairment or dementia (Clinical Dementia Rating global score of 0 at all assessments). Using cognitive and neuropathologic data collected between 2005 and 2013 from the 34 National Institute on Aging-sponsored Alzheimer's Disease Centers, cognitive trajectories were compared for persons with and without evidence of AD neuropathologic change. We evaluated rates of decline in 4 domains (episodic memory, language, attention/working memory, executive function). The significance of the differences (β) in rates of decline was tested using linear regression, adjusting for age, education, sex, and other neuropathologic lesions. RESULTS: Participants who had low to high levels of AD neuropathologic change (n = 131) showed a greater rate of decline on the attention/working memory domain score (β = -0.11; 95% confidence interval = -0.19, -0.02; p = 0.02) when compared to 80 participants who died without evidence of AD neuropathologic change. CONCLUSIONS: Clinically normal individuals who come to autopsy with AD neuropathologic change exhibit subtle evidence of declining cognitive trajectories for attention/working memory.
OBJECTIVE: To determine whether asymptomatic persons with Alzheimer disease (AD) neuropathologic change differ in the trajectory of their cognitive performance compared to asymptomatic persons without AD neuropathologic change. METHODS: Longitudinal performance on standard neuropsychological tests was examined in participants who died within 2 years of their last cognitive assessment and who were never diagnosed with mild cognitive impairment or dementia (Clinical Dementia Rating global score of 0 at all assessments). Using cognitive and neuropathologic data collected between 2005 and 2013 from the 34 National Institute on Aging-sponsored Alzheimer's Disease Centers, cognitive trajectories were compared for persons with and without evidence of AD neuropathologic change. We evaluated rates of decline in 4 domains (episodic memory, language, attention/working memory, executive function). The significance of the differences (β) in rates of decline was tested using linear regression, adjusting for age, education, sex, and other neuropathologic lesions. RESULTS:Participants who had low to high levels of AD neuropathologic change (n = 131) showed a greater rate of decline on the attention/working memory domain score (β = -0.11; 95% confidence interval = -0.19, -0.02; p = 0.02) when compared to 80 participants who died without evidence of AD neuropathologic change. CONCLUSIONS: Clinically normal individuals who come to autopsy with AD neuropathologic change exhibit subtle evidence of declining cognitive trajectories for attention/working memory.
Authors: Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Ira Driscoll; Susan M Resnick; Juan C Troncoso; Yang An; Richard O'Brien; Alan B Zonderman Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Jason Hassenstab; Sarah E Monsell; Charles Mock; Catherine M Roe; Nigel J Cairns; John C Morris; Walter Kukull Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Shruti Mishra; Brian A Gordon; Yi Su; Jon Christensen; Karl Friedrichsen; Kelley Jackson; Russ Hornbeck; David A Balota; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger Journal: Neuroimage Date: 2017-07-26 Impact factor: 6.556
Authors: Sarah E Monsell; Charles Mock; David W Fardo; Sarah Bertelsen; Nigel J Cairns; Catherine M Roe; Sally R Ellingson; John C Morris; Alison M Goate; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2017 Jul-Sep Impact factor: 2.703
Authors: Laura B Zahodne; Melanie M Wall; Nicole Schupf; Richard Mayeux; Jennifer J Manly; Yaakov Stern; Adam M Brickman Journal: J Neurol Date: 2015-08-11 Impact factor: 4.849
Authors: Gregory S Day; Erik S Musiek; Catherine M Roe; Joanne Norton; Alison M Goate; Carlos Cruchaga; Nigel J Cairns; John C Morris Journal: JAMA Neurol Date: 2016-09-01 Impact factor: 18.302